Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response or Intolerance to One Anti-Tumor Necrosis Factor (Anti-TNF) Agent
- First Posted Date
- 2012-07-17
- Last Posted Date
- 2016-08-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 505
- Registration Number
- NCT01641952
A Study of RO5429083 Alone or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia
- First Posted Date
- 2012-07-16
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 44
- Registration Number
- NCT01641250
A Retrospective Chart Review on the Use of Biologics in Monotherapy for the Treatment of Patients With Rheumatoid Arthritis
Completed
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2012-07-13
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 320
- Registration Number
- NCT01640548
A Study of Ritonavir-Boosted Invirase (Saquinavir) in Treatment-Naïve HIV-1 Infected Patients
Phase 1
Completed
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2012-07-12
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 23
- Registration Number
- NCT01638650
A Study of A High Concentration Liquid Formulation Versus A Lyophilized Formulation of Gantenerumab in Healthy Volunteers
- First Posted Date
- 2012-07-10
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 120
- Registration Number
- NCT01636531
A Study of Bitopertin (RO4917838) in Healthy Male Volunteers
- First Posted Date
- 2012-07-10
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 71
- Registration Number
- NCT01636492
A Study of RO5045337 in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia
- First Posted Date
- 2012-07-09
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 43
- Registration Number
- NCT01635296
An Non-Interventional Study of Patients With Persistent Symptoms of Schizophrenia
Completed
- Conditions
- Schizophrenia
- First Posted Date
- 2012-07-06
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1433
- Registration Number
- NCT01634542
A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma
- First Posted Date
- 2012-07-02
- Last Posted Date
- 2018-02-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 135
- Registration Number
- NCT01632228
- Locations
- 🇩🇪
Ärztehaus Velen, Ibbenbühren, Germany
🇨🇦McGill University; Montreal Neurological Institute; Oncology, Montreal, Quebec, Canada
🇨🇦London Health Sciences Centre, London, Ontario, Canada
A Single Dose Study of Radiolabeled RO4602522 in Healthy Volunteers
- First Posted Date
- 2012-06-29
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 6
- Registration Number
- NCT01631422
© Copyright 2025. All Rights Reserved by MedPath